BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tian Z, Niu X, Yao W. Receptor Tyrosine Kinases in Osteosarcoma Treatment: Which Is the Key Target? Front Oncol 2020;10:1642. [PMID: 32984034 DOI: 10.3389/fonc.2020.01642] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 6.5] [Reference Citation Analysis]
Number Citing Articles
1 Kim J, Berlow NE, Lathara M, Bharathy N, Martin LR, Purohit R, Cleary MM, Liu Q, Michalek JE, Srinivasa G, Cole BL, Chen SD, Keller C. Sensitization of osteosarcoma to irradiation by targeting nuclear FGFR1. Biochemical and Biophysical Research Communications 2022. [DOI: 10.1016/j.bbrc.2022.07.002] [Reference Citation Analysis]
2 Tzanakakis GN, Giatagana EM, Berdiaki A, Spyridaki I, Hida K, Neagu M, Tsatsakis AM, Nikitovic D. The Role of IGF/IGF-IR-Signaling and Extracellular Matrix Effectors in Bone Sarcoma Pathogenesis. Cancers (Basel) 2021;13:2478. [PMID: 34069554 DOI: 10.3390/cancers13102478] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
3 Pearson AD, Gaspar N, Janeway K, Campbell-Hewson Q, Lawlor ER, Copland C, Karres D, Norga K, Benzaghou F, Weiner S, Weigel B, Weiss AR, Strauss SJ, Smith M, Setty BA, Seibel N, Scobie N, Pappo A, Okpara CE, Nysom K, McDonough J, Marshall LV, Ludwinski D, Ligas F, Lesa G, Knudsen S, Kauh J, Hsieh A, Heenen D, Hawkins DS, Graham A, Garmey E, DuBois SG, Fox E, Donoghue M, de Rojas T, Chung J, Casanova M, Brennan B, Bishop M, Buenger V, Reaman G, Vassal G. Paediatric Strategy Forum for medicinal product development of multi-targeted kinase inhibitors in bone sarcomas: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration. Eur J Cancer 2022;173:71-90. [PMID: 35863108 DOI: 10.1016/j.ejca.2022.06.008] [Reference Citation Analysis]
4 Chen B, Zeng Y, Liu B, Lu G, Xiang Z, Chen J, Yu Y, Zuo Z, Lin Y, Ma J. Risk Factors, Prognostic Factors, and Nomograms for Distant Metastasis in Patients With Newly Diagnosed Osteosarcoma: A Population-Based Study. Front Endocrinol (Lausanne) 2021;12:672024. [PMID: 34393996 DOI: 10.3389/fendo.2021.672024] [Reference Citation Analysis]
5 Zoumpoulidou G, Alvarez-Mendoza C, Mancusi C, Ahmed RM, Denman M, Steele CD, Tarabichi M, Roy E, Davies LR, Manji J, Cristalli C, Scotlandi K, Pillay N, Strauss SJ, Mittnacht S. Therapeutic vulnerability to PARP1,2 inhibition in RB1-mutant osteosarcoma. Nat Commun 2021;12:7064. [PMID: 34862364 DOI: 10.1038/s41467-021-27291-8] [Reference Citation Analysis]
6 Argenziano M, Tortora C, Pota E, Di Paola A, Di Martino M, Di Leva C, Di Pinto D, Rossi F. Osteosarcoma in Children: Not Only Chemotherapy. Pharmaceuticals (Basel) 2021;14:923. [PMID: 34577623 DOI: 10.3390/ph14090923] [Reference Citation Analysis]
7 Wang J, Zhang Z, Qiu C, Wang J. MicroRNA-519d-3p antagonizes osteosarcoma resistance against cisplatin by targeting PD-L1. Mol Carcinog 2021. [PMID: 34780678 DOI: 10.1002/mc.23370] [Reference Citation Analysis]
8 Koroki K, Kanogawa N, Maruta S, Ogasawara S, Iino Y, Obu M, Okubo T, Itokawa N, Maeda T, Inoue M, Haga Y, Seki A, Okabe S, Koma Y, Azemoto R, Atsukawa M, Itobayashi E, Ito K, Sugiura N, Mizumoto H, Unozawa H, Iwanaga T, Sakuma T, Fujita N, Kanzaki H, Kobayashi K, Kiyono S, Nakamura M, Saito T, Kondo T, Suzuki E, Ooka Y, Nakamoto S, Tawada A, Chiba T, Arai M, Kanda T, Maruyama H, Kato J, Kato N. Posttreatment after Lenvatinib in Patients with Advanced Hepatocellular Carcinoma. Liver Cancer 2021;10:473-84. [PMID: 34721509 DOI: 10.1159/000515552] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Guo M, Liu Z, Si J, Zhang J, Zhao J, Guo Z, Xie Y, Zhang H, Gan L. Cediranib Induces Apoptosis, G1 Phase Cell Cycle Arrest, and Autophagy in Non-Small-Cell Lung Cancer Cell A549 In Vitro. Biomed Res Int 2021;2021:5582648. [PMID: 33860036 DOI: 10.1155/2021/5582648] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Liu R, Hu Y, Liu T, Wang Y. Profiles of immune cell infiltration and immune-related genes in the tumor microenvironment of osteosarcoma cancer. BMC Cancer 2021;21:1345. [PMID: 34922489 DOI: 10.1186/s12885-021-09042-6] [Reference Citation Analysis]
11 Ye G, Huang M, Li Y, Ouyang J, Chen M, Wen Q, Li X, Zeng H, Long P, Fan Z, Yin J, Ye W, Zhang D. The FAP α -activated prodrug Z-GP-DAVLBH inhibits the growth and pulmonary metastasis of osteosarcoma cells by suppressing the AXL pathway. Acta Pharm Sin B 2022;12:1288-304. [PMID: 35530139 DOI: 10.1016/j.apsb.2021.08.015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Higuchi T, Igarashi K, Yamamoto N, Hayashi K, Kimura H, Miwa S, Bouvet M, Tsuchiya H, Hoffman RM. Multikinase-Inhibitor Screening in Drug-resistant Osteosarcoma Patient-derived Orthotopic Xenograft Mouse Models Identifies the Clinical Potential of Regorafenib. Cancer Genomics Proteomics 2021;18:637-43. [PMID: 34479916 DOI: 10.21873/cgp.20286] [Reference Citation Analysis]
13 Meazza C, Asaftei SD. State-of-the-art, approved therapeutics for the pharmacological management of osteosarcoma. Expert Opin Pharmacother 2021;:1-12. [PMID: 34058096 DOI: 10.1080/14656566.2021.1936499] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Just MA, Van Mater D, Wagner LM. Receptor tyrosine kinase inhibitors for the treatment of osteosarcoma and Ewing sarcoma. Pediatr Blood Cancer 2021;68:e29084. [PMID: 33894051 DOI: 10.1002/pbc.29084] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Moukengue B, Lallier M, Marchandet L, Baud’huin M, Verrecchia F, Ory B, Lamoureux F. Origin and Therapies of Osteosarcoma. Cancers 2022;14:3503. [DOI: 10.3390/cancers14143503] [Reference Citation Analysis]
16 Sun X, Shan HJ, Yin G, Zhang XY, Huang YM, Li HJ. The anti-osteosarcoma cell activity by the sphingosine kinase 1 inhibitor SKI-V. Cell Death Discov 2022;8:48. [PMID: 35115496 DOI: 10.1038/s41420-022-00838-4] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
17 Li W, Dong S, Wang B, Wang H, Xu C, Zhang K, Li W, Hu Z, Li X, Liu Q, Wu R, Yin C. The Construction and Development of a Clinical Prediction Model to Assess Lymph Node Metastases in Osteosarcoma. Front Public Health 2021;9:813625. [PMID: 35071175 DOI: 10.3389/fpubh.2021.813625] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
18 Tang X. CORR Insights®: Identification of a Novel MAN1A1-ROS1 Fusion Gene Through mRNA-based Screening for Tyrosine Kinase Gene Aberrations in a Patient with Leiomyosarcoma. Clin Orthop Relat Res 2021;479:853-4. [PMID: 33394756 DOI: 10.1097/CORR.0000000000001625] [Reference Citation Analysis]
19 Bellantoni AJ, Wagner LM. Pursuing Precision: Receptor Tyrosine Kinase Inhibitors for Treatment of Pediatric Solid Tumors. Cancers (Basel) 2021;13:3531. [PMID: 34298746 DOI: 10.3390/cancers13143531] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Koons N, Amato N, Sauer S, Warshawsky D, Barkan D, Khanna C. Assessing a Novel 3D Assay System for Drug Screening against OS Metastasis. Pharmaceuticals (Basel) 2021;14:971. [PMID: 34681195 DOI: 10.3390/ph14100971] [Reference Citation Analysis]
21 Xie L, Xu J, Sun X, Li X, Liu K, Liang X, Zhou Z, Zhuang H, Sun K, Wu Y, Gu J, Guo W. Apatinib plus ifosfamide and etoposide for relapsed or refractory osteosarcoma: A retrospective study in two centres. Oncol Lett 2021;22:552. [PMID: 34093773 DOI: 10.3892/ol.2021.12813] [Reference Citation Analysis]
22 Harris MA, Hawkins CJ. Recent and Ongoing Research into Metastatic Osteosarcoma Treatments. Int J Mol Sci 2022;23:3817. [PMID: 35409176 DOI: 10.3390/ijms23073817] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]